Compare Stocks: CRVS, CDNA, CELC, and ACAD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$19.78	$26.39	$19.32 ▼ $30.96	$3.41B	0.88	2.49 million shs	1.47 million shs
CDNA CareDx	$63.67	$53.19	$13.95 ▼ $72.51	$3.29B	2.38	1.49 million shs	895,598 shs
CELC Celcuity	$67.94	$86.01	$45.03 ▼ $151.02	$3.32B	0.1	1.32 million shs	1.28 million shs
CRVS Corvus Pharmaceuticals	$10.52	$13.25	$6.39 ▼ $26.95	$884.94M	1.44	1.32 million shs	1.03 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-0.85%	-28.93%	-22.43%	-1.40%
CDNA CareDx	0.00%	-5.18%	+26.68%	+121.38%	+342.46%
CELC Celcuity	0.00%	-5.77%	-18.59%	-34.54%	+47.47%
CRVS Corvus Pharmaceuticals	0.00%	-3.49%	-18.51%	-28.48%	+51.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$19.78	$26.39	$19.32 ▼ $30.96	$3.41B	0.88	2.49 million shs	1.47 million shs
CDNA CareDx	$63.67	$53.19	$13.95 ▼ $72.51	$3.29B	2.38	1.49 million shs	895,598 shs
CELC Celcuity	$67.94	$86.01	$45.03 ▼ $151.02	$3.32B	0.1	1.32 million shs	1.28 million shs
CRVS Corvus Pharmaceuticals	$10.52	$13.25	$6.39 ▼ $26.95	$884.94M	1.44	1.32 million shs	1.03 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-0.85%	-28.93%	-22.43%	-1.40%
CDNA CareDx	0.00%	-5.18%	+26.68%	+121.38%	+342.46%
CELC Celcuity	0.00%	-5.77%	-18.59%	-34.54%	+47.47%
CRVS Corvus Pharmaceuticals	0.00%	-3.49%	-18.51%	-28.48%	+51.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$32.71	65.37% Upside
CDNA CareDx	2.38	Hold	$54.00	-15.19% Downside
CELC Celcuity	2.83	Moderate Buy	$154.25	127.04% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	216.86% Upside

Current Analyst Ratings Breakdown

Latest CRVS, CDNA, CELC, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
10/8/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$37.00 ➝ $36.00
10/2/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/30/2026	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$140.00 ➝ $134.00
9/28/2026	ACAD ACADIA Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $31.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $35.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $33.00
9/25/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$36.00 ➝ $33.00
9/24/2026	ACAD ACADIA Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.14B	2.99	$0.89 per share	22.30	$7.25 per share	2.73
CDNA CareDx	$458.09M	7.19	N/A	N/A	$5.89 per share	10.81
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	83.00	$0.73 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	8.91	20.18	N/A	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	30.76	101.06	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)

Latest CRVS, CDNA, CELC, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ACAD ACADIA Pharmaceuticals	$0.2002	N/A	N/A	N/A	$332.81 million	N/A
11/3/2026	Q3 2026	CDNA CareDx	$0.2552	N/A	N/A	N/A	$121.95 million	N/A
11/3/2026	Q3 2026	CRVS Corvus Pharmaceuticals	-$0.1921	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
CDNA CareDx	N/A	4.58	4.51
CELC Celcuity	6.04	8.93	8.93
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CDNA CareDx	N/A
CELC Celcuity	63.33%
CRVS Corvus Pharmaceuticals	46.64%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
CDNA CareDx	2.40%
CELC Celcuity	13.33%
CRVS Corvus Pharmaceuticals	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.31 million	127.16 million	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable

CRVS, CDNA, CELC, and ACAD Headlines

Recent News About These Companies

Corvus Begins Patient Enrollment In Phase 1b Soquelitinib Trial For Hidradenitis Suppurativa

October 1, 2026 | rttnews.com

Corvus Pharmaceuticals begins Phase 1b trial of soquelitinib for skin disease

September 30, 2026 | streetinsider.com

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

September 30, 2026 | globenewswire.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened

September 29, 2026 | marketbeat.com

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Consensus Rating of "Moderate Buy" from Analysts

September 28, 2026 | marketbeat.com

Bank of America Corp DE Acquires New Shares in Corvus Pharmaceuticals, Inc. $CRVS

September 26, 2026 | marketbeat.com

Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?

September 25, 2026 | finance.yahoo.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.7% - Here's Why

September 23, 2026 | marketbeat.com

Squarepoint Ops LLC Sells 79,691 Shares of Corvus Pharmaceuticals, Inc. $CRVS

September 20, 2026 | marketbeat.com

CRVS Share News Today

September 17, 2026 | uk.investing.com

Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald

September 16, 2026 | streetinsider.com

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

September 3, 2026 | globenewswire.com

Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment

August 27, 2026 | seekingalpha.com

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

August 27, 2026 | finance.yahoo.com

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

August 27, 2026 | globenewswire.com

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

August 17, 2026 | finance.yahoo.com

Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value

August 12, 2026 | seekingalpha.com

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

August 10, 2026 | seekingalpha.com

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CDNA, CELC, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$19.78 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$19.89 +0.11 (+0.54%)

As of 05:46 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CareDx NASDAQ:CDNA

$63.67 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$63.84 +0.17 (+0.27%)

As of 06:37 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Celcuity NASDAQ:CELC

$67.94 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$67.94 0.00 (0.00%)

As of 04:01 AM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Corvus Pharmaceuticals NASDAQ:CRVS

$10.52 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.40 -0.12 (-1.12%)

As of 05:16 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, CDNA, CELC, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, CDNA, CELC, and ACAD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, CDNA, CELC, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CDNA, CELC, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CareDx NASDAQ:CDNA

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, CDNA, CELC, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, CDNA, CELC, and ACAD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, CDNA, CELC, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CDNA, CELC, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CareDx NASDAQ:CDNA

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools